- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05911243
Viabilidad de la acupresión auricular para el apetito y el peso en pacientes con cáncer gástrico, esofágico y pancreático en estadio II-IV
Un ensayo controlado aleatorizado que prueba los efectos de una intervención de acupresión sobre el apetito y el peso en pacientes con cáncer gástrico, esofágico y pancreático: un estudio piloto y de viabilidad
This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatment tolerance and adherence, and reduces overall patient quality of life. Auricular acupressure is a form of micro-acupuncture that exerts its effect by stimulating the central nervous system using adhesive taped pellets applied to specific locations on the external ear. The use of these pellets to deliver auricular acupressure has been shown to improve pain, fatigue, insomnia, nausea and vomiting, depression, and quality of life in both cancer and non-cancer settings. Auricular acupressure is a safe, inexpensive, and non-invasive approach to addressing cancer-related symptoms and treatment side-effects and may be effective at improving appetite and weight loss in stage II-IV gastric, esophageal, and pancreatic cancer patients.
Descripción general del estudio
Estado
Condiciones
- Cáncer de páncreas en estadio II AJCC v8
- Cáncer de páncreas en estadio III AJCC v8
- Cáncer de páncreas en estadio IV AJCC v8
- Cáncer gástrico en estadio clínico III AJCC v8
- Cáncer gástrico en estadio clínico IV AJCC v8
- Adenocarcinoma de esófago en estadio clínico II AJCC v8
- Carcinoma de células escamosas de esófago en estadio clínico II AJCC v8
- Cáncer gástrico en estadio clínico II AJCC v8
- Adenocarcinoma de esófago en estadio clínico III AJCC v8
- Carcinoma de células escamosas de esófago en estadio clínico III AJCC v8
- Adenocarcinoma de esófago en estadio clínico IV AJCC v8
- Carcinoma de células escamosas de esófago en estadio clínico IV AJCC v8
Descripción detallada
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.
ARM II: Patients receive usual care on study. Patients also undergo collection of blood samples on study.
After completion of study treatment, patients in Arm II are followed up at 8 weeks after active treatment ends.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18-65 years of age
- Stage II-IV gastric, esophageal, or pancreatic cancer
- Appetite score on visual analog scale ≤ 70/100
- At least 60 days of planned systemic treatment, whether already initiated or scheduled to be initiated
- Access to phone and electronic device for study contacts and questionnaires
- Willing and able to attend 4 in-person auricular acupressure treatments at the Fred Hutch South Lake Union Clinic
- Willing and able to perform 4 at-home self-applied treatments of auricular acupressure
- Participants must not have received acupressure or acupuncture for low appetite within last 30 days
- Participants must not be actively using corticosteroids, mirtazapine (Remeron), olanzapine (Zyprexa), or Marinol for appetite stimulation at baseline
- Participants must be able to intake food orally and not require sole or supplemental intravenous nutrition at baseline
- Participants must not have a history of physiological eating disorders (e.g., anorexia nervosa) in the last 3 years
- Participants must not have a current known or diagnosed immunodeficiency
- Participants must have an intact auricular pinna
- Able to understand and willing to sign written informed consent in English
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm I (acupressure therapy)
Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study. |
Ancillary studies
Otros nombres:
Undergo collection of blood samples
Otros nombres:
Receive usual care
Otros nombres:
Undergo auricular acupressure
Otros nombres:
|
|
Comparador activo: Arm II (usual care)
Patients receive usual care on study. Patients also undergo collection of blood samples on study. |
Ancillary studies
Otros nombres:
Undergo collection of blood samples
Otros nombres:
Receive usual care
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Accrual (Feasibility)
Periodo de tiempo: Up to 2 years, during study accrual
|
Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period. |
Up to 2 years, during study accrual
|
|
Retention (Feasibility)
Periodo de tiempo: Up to 8 weeks
|
Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit. |
Up to 8 weeks
|
|
Intervention Adherence (Feasibility)
Periodo de tiempo: Up to 8 weeks
|
Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8. |
Up to 8 weeks
|
|
Intervention Fidelity (Feasibility)
Periodo de tiempo: Up to 8 weeks
|
Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis. |
Up to 8 weeks
|
|
Acceptability (Feasibility)
Periodo de tiempo: Up to 16 weeks
|
Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews. |
Up to 16 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Appetite
Periodo de tiempo: Baseline to week 4
|
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response. |
Baseline to week 4
|
|
Change in Appetite
Periodo de tiempo: Baseline to week 8
|
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response. |
Baseline to week 8
|
|
Change in Body Weight (kg)
Periodo de tiempo: Baseline to week 4
|
Analyses will assess change in each outcome as a change from baseline to week 4. |
Baseline to week 4
|
|
Change in Body Weight (kg)
Periodo de tiempo: Baseline to week 8
|
Analyses will assess change in each outcome as a change from baseline to week 8. |
Baseline to week 8
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Blake Langley, Fred Hutch/University of Washington Cancer Consortium
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Calidad de la atención médica
- Terapias complementarias
- Modalidades de fisioterapia
- Indicadores de calidad, atención médica
- Rehabilitación
- Pautas como tema
- Garantía de calidad, atención médica
- Terapia, tejido blando
- Manipulaciones musculoesqueléticas
- Estándar de cuidado
- Manejo de muestras
- Directrices de práctica como tema
- Acupresión
Otros números de identificación del estudio
- RG1123492
- RG1123492 (Otro identificador: Fred Hutch/University of Washington Cancer Consortium)
- NCI-2023-03942 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- 3KL2TR002317 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data that underlie the results reported in published articles after de-identification may be made available upon request (text, tables, figures, and appendices).
Marco de tiempo para compartir IPD
Beginning 6 months and ending 36 months after publication of results or study protocol, as requested.
Criterios de acceso compartido de IPD
Researchers and investigators who: 1) provide a methodologically sound proposal to expand on aims in the original, approved proposal; and/or 2) aim to conduct individual, participant-level meta-analyses. Proposals should be directed to blangley@fredhutch.org. To gain access, data requestors will need to sign a data access agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .